All In Biotech

Drug Trial Radar · NCT07564401

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 16, 2026

Primary completion

Mar 3, 2031

Study completion Mar 3, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.

Conditions

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

  • DJI136Drug

    DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All study parts: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to approximately 2 years
  2. All study parts: Incidence and severity of dose-limiting toxicities (DLTs)Time frame: 28 days
  3. Phase II Group A: Overall response rate (ORR) as per RECIST v1.1Time frame: Up to approximately 2 years

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Novartis Investigative Site

    Clayton, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.